Literature DB >> 21704227

The microenvironment and molecular biology of the multiple myeloma tumor.

Miguel Lemaire1, Sarah Deleu, Elke De Bruyne, Els Van Valckenborgh, Eline Menu, Karin Vanderkerken.   

Abstract

Multiple myeloma (MM) is a deadly plasma cell cancer that resides in the bone marrow (BM). Numerous studies have demonstrated the involvement of the BM microenvironment supporting tumor growth, angiogenesis, bone disease and drug resistance. Reciprocal interactions between the different components of the BM microenvironment and the MM cells are necessary to regulate migration, differentiation, proliferation and survival of the malignant plasma cells. In this review we focus on the interactions and molecular mechanisms by which the BM microenvironment exert these effects. Better understanding of these interactions and the study of the epigenetic changes that tumor cells undergo are necessary in order to improve current treatments and for the discovery of new therapies that may eventually lead to a potential cure.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21704227     DOI: 10.1016/B978-0-12-386469-7.00002-5

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  31 in total

1.  Guest editorial: understanding the pathogenesis and the evolving treatment paradigm for multiple myeloma in the era of novel agents.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-13       Impact factor: 2.490

Review 2.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

3.  Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

Authors:  Michal Bar-Natan; Dina Stroopinsky; Katarina Luptakova; Maxwell D Coll; Arie Apel; Hasan Rajabi; Athalia R Pyzer; Kristen Palmer; Michaela R Reagan; Myrna R Nahas; Rebecca Karp Leaf; Salvia Jain; Jon Arnason; Irene M Ghobrial; Kenneth C Anderson; Donald Kufe; Jacalyn Rosenblatt; David Avigan
Journal:  Br J Haematol       Date:  2017-01-20       Impact factor: 6.998

Review 4.  Extracellular vesicles and blood diseases.

Authors:  Shosaku Nomura
Journal:  Int J Hematol       Date:  2017-01-27       Impact factor: 2.490

Review 5.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

6.  Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways.

Authors:  Daniel J Medina; Lauri Goodell; John Glod; Céline Gélinas; Arnold B Rabson; Roger K Strair
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

Review 7.  Evolutionary biology of high-risk multiple myeloma.

Authors:  Charlotte Pawlyn; Gareth J Morgan
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

8.  Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium.

Authors:  Brenda M Birmann; Marian L Neuhouser; Bernard Rosner; Demetrius Albanes; Julie E Buring; Graham G Giles; Qing Lan; I-Min Lee; Mark P Purdue; Nathaniel Rothman; Gianluca Severi; Jian-Min Yuan; Kenneth C Anderson; Michael Pollak; Nader Rifai; Patricia Hartge; Ola Landgren; Lawrence Lessin; Jarmo Virtamo; Robert B Wallace; JoAnn E Manson; Graham A Colditz
Journal:  Blood       Date:  2012-10-16       Impact factor: 22.113

9.  Low intensity vibration mitigates tumor progression and protects bone quantity and quality in a murine model of myeloma.

Authors:  Gabriel M Pagnotti; M Ete Chan; Benjamin J Adler; Kenneth R Shroyer; Janet Rubin; Steven D Bain; Clinton T Rubin
Journal:  Bone       Date:  2016-06-02       Impact factor: 4.398

10.  IRF4 promotes cell proliferation by JNK pathway in multiple myeloma.

Authors:  Sensen Zhang; Jiaren Xu; Shuang Wu; Rong Wang; Xiaoyan Qu; Wenjun Yu; Jiangyong Li; Lijuan Chen
Journal:  Med Oncol       Date:  2013-05-12       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.